This New England Lymphoma Rounds provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the local area. Please note that this program is only open to practicing lymphoma physicians and industry supporters. Please continue to check this page for updates. For updates, please ensure you are subscribed to receive emails from the Lymphoma Research Foundation
Full Lymphoma Rounds COVID policy (updated 06.30.2023) can be accessed here and required for review prior to submitting a registration.
Lymphoma Rounds: New England
DATE: Thursday, April 11, 2024
TIME: Networking 6:00 PM – 7:00 PM ET
Program 7:00 PM – 8:30 PM ET
LOCATION: The Westin Copley Place
10 Huntington Avenue
Boston, MA 02116
This program is free for healthcare professionals; however, pre-registration is required.
Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please email LRF at firstname.lastname@example.org. Exhibit opportunities are available.
Companies that have secured a national exhibit sponsorship for Lymphoma Rounds must still rsvp by emailing email@example.com at least one week before the program to confirm their attendance.
PROGRAM AGENDA – TBA
ABOUT THE PROGRAM
The Lymphoma Rounds program provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the local area.
At the conclusion of this educational activity, the participant should be better able to:
- Summarize the latest developments in lymphoma diagnosis, treatment and management.
- Apply best practices for treating lymphoma patients.
- Inform patients about potential clinical trial opportunities.
- Establish a network of health care professionals who work with lymphoma patients.
This is the second program in the 2023-24 New England Rounds series.
New EnGland Lymphoma Rounds Steering Committee
Baystate Medical Center
Armen Asik, MD
Beth Israel Deaconess Medical Center
Jon Arnason, MD
Michael Leukam, MD
Boston University School of Medicine
J. Mark Sloan, MD
Brown University School of Medicine
Adam Olszewski, MD
Dana-Farber Cancer Institute
Jorge Castillo, MD
Ann LaCasce, MD, MSc
Dartmouth-Hitchcock Medical Center
Elizabeth Bengtson, MD
Erick Lansigan, MD
Lahey Hospital and Medical Center
Tarun Kewalramani, MD
Massachusetts General Hospital Center
Jeremy Abramson, MD, MSc (chair)
Jeffrey Barnes, MD, PhD
Saint Francis Hospital in Hartford
Syed Ali, MD
Tufts Cancer Center
Andreas Klein, MD
UMass Memorial Medical Center
Jan Cerny, MD, PhD, FACP
Muthalagu Ramanathan, MD
University of Vermont College of Medicine
Julian Sprague, MD, PhD
Yale University School of Medicine
Francine Foss, MD
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Lymphoma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Lymphoma Research Foundation and the Penn State College of Medicine
This activity is supported by educational grants from:
AbbVie, Inc., Acrotech, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, BTG International Inc., Genmab, Kite Pharma Inc., Kyowa Kirin, Lilly USA, MorphoSys, Pharmacyclics LLC, an AbbVie Company / Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Pfizer